Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery an
GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease
07:00am, Wednesday, 12'th Jun 2024
OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership wil
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:45am, Tuesday, 11'th Jun 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK 'still appealing' despite US legal setback says broker
04:33am, Tuesday, 11'th Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) is 'still appealing' - even in the wake of a significant legal setback, according to regional broker Shore Capital, which set out its 'buy' case in the wake of the UK drug
GSK appeals Delaware Zantac ruling
03:16am, Tuesday, 11'th Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) and other pharmaceutical companies asked a Delaware court to allow an appeal of a ruling permitting over 70,000 lawsuits claiming Zantac causes cancer. Analysts had expec
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
09:55am, Monday, 10'th Jun 2024
GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.
GSK RSV jab receives label expansion from US regulator
03:16am, Monday, 10'th Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) has confirmed that the US Food & Drug Administration has approved Arexvy for preventing respiratory syncytial virus (RSV) in adults aged 50 to 59 at increased risk of sever
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--US FDA approves expanded age indication for GSK's AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
06:21pm, Friday, 07'th Jun 2024
The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus. The age
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
06:06pm, Friday, 07'th Jun 2024
The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus vaccine on Friday in adults aged between 50 and 59, making it the first shot endorsed for that age
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
05:23pm, Thursday, 06'th Jun 2024
Pharma stocks have two unique characteristics that can make them great investments for many individuals. First, unlike the vast majority of equities, undervalued pharma stocks can rally even when the
GSK: Still reasons to be cheerful rather than fearful after 'nightmare' Monday
08:04am, Tuesday, 04'th Jun 2024
What was supposed to be a stellar day for GSK PLC (LSE:GSK, NYSE:GSK) at the annual American Society of Clinical Oncology turned into quite the opposite. News of an adverse ruling in a Delaware court
GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know.
03:44pm, Monday, 03'rd Jun 2024
Many investors expected today's move in GlaxoSmithKline (NYSE: GSK ), with shares of GSK stock plunging more than 8% in early afternoon trading. That's because, on Friday, a Delaware judge ruled that
GSK Stock Dives After Judge Allows Zantac Cancer Lawsuits To Go Forward
12:50pm, Monday, 03'rd Jun 2024
American depositary receipts (ADRs) of GSK Plc (GSK) tumbled in intraday trading Monday after a Delaware court ruled that lawsuits claiming the drugmaker's discontinued heartburn treatment, Zantac, ca
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
12:41pm, Monday, 03'rd Jun 2024
GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.
